Form 4: Ironwood Pharmaceuticals Director Stock Grant

Marla L. Kessler, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Summary

• Marla L. Kessler, a Director of Ironwood Pharmaceuticals Inc. (IRWD), was granted 63,481 shares of Class A Common Stock on June 16, 2026.
• This grant was made under the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
• The restricted stock vests in full on the day before the annual stockholders' meeting for the next calendar year.
• Following this transaction, Ms. Kessler beneficially owns 229,364 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation is being provided through equity, aligning director interests with shareholders.
• The grant of 63,481 shares represents a significant equity award to a key governance member.

Future Outlook

The restricted stock granted vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year, indicating a future vesting event.

Industry Context

StockSavvy.ai notes that equity-based compensation for non-employee directors is a common practice in the pharmaceutical industry to attract and retain experienced board members and align their interests with long-term company performance.

Corporate Governance

Related Party Transactions

• Grant of restricted stock to Director Marla L. Kessler.

Stakeholder Impact

• Shareholders: The grant of equity to directors aligns their interests with shareholders, potentially leading to better governance and long-term value creation.
• Employees: This filing does not directly impact employees.

Next Steps

• Vesting of the granted restricted stock on the date immediately preceding the annual stockholders' meeting for the next calendar year.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, Director Compensation, Stock Grant, Class A Common Stock, Beneficial Ownership, SEC Form 4